Abstract:
:In order to establish diagnostic criteria for hypocellular acute leukemia (HL), we have reviewed 32 cases selected on the basis of hypothetical 40% or less cellularity, by focusing on morphology, immunophenotype, karyotype and response to low dose Ara-C (LDAC) regimen and compared them with 40 cases of myelodysplastic syndrome (MDS) and 66 cases of overt acute myeloid leukemia (AML). The onset age ranged from 44 to 75 years (median 67 years). Bone marrow (BM) cellularity ranged from 12.4 to 39.8% (mean 29.8%) in HL, being significantly lower than in MDS (mean 80.7%) or AML (mean 86.4%) (P < 0.001). All reviewed cases characteristically showed smoldering clinical course, bi- or pancytopenia with rare leukemic blasts in the peripheral blood (PB), proliferation of type I leukemic blasts in the BM and markedly reduced background hematopoietic cells with some dysplastic changes in 12/32 cases (37.50/6). Blast percentage (blast %) in the BM ranged from 38.2 to 93.7% (mean 57.3%) in all nucleated cells (ANC). Although a considerable number of cases had blasts with negative or very low myeloperoxidase activity, immunophenotyping revealed that the leukemic blasts in HL had only myeloid markers. Karyotyping revealed non-random chromosome abnormalities in 30% of cases analyzed, which were considerably different from those seen in MDS. With LDAC regimen, a significantly higher CR rate (13/20 cases: 65.0%) was gained in HL than in RAEB/RAEB-t (0%) and overt AML in the elderly cases (27.3%) (P < 0.05). In CR, most cases showed recovery to normocellular BM with an apparent normalization of PB parameters. However, 12 CR cases relapsed 4-12 months later; most of which again showed hypocellular BM. These results indicate that HL is a distinct subtype of AML characterized by slow but distinct proliferation of immature myeloid blasts and by unique hematological features distinct from MDS or overt AML in the elderly. We propose the following diagnostic criteria: (1) pancytopenia with rare appearance of blasts in PB; (2) less than 40% BM hypocellularity; (3) more than 30% blasts in BM-ANC; and (4) myeloid phenotypes of leukemic blasts by MPO staining and/or immunophenotyping.
journal_name
Leuk Resjournal_title
Leukemia researchauthors
Nagai K,Kohno T,Chen YX,Tsushima H,Mori H,Nakamura H,Jinnai I,Matsuo T,Kuriyama K,Tomonaga M,Bennett JMdoi
10.1016/0145-2126(95)00136-0subject
Has Abstractpub_date
1996-07-01 00:00:00pages
563-74issue
7eissn
0145-2126issn
1873-5835pii
0145-2126(95)00136-0journal_volume
20pub_type
杂志文章abstract::Smoking may be associated with accelerated erythropoiesis, leukocytosis and thrombocytosis, which are also hallmarks in patients with polycythemia vera, essential thrombocythemia and early stages of myelofibrosis (MPNs). The JAK-STAT and NF-κB signaling pathways are activated in both smokers and in patients with MPNs....
journal_title:Leukemia research
pub_type: 杂志文章,评审
doi:10.1016/j.leukres.2015.09.002
更新日期:2015-09-09 00:00:00
abstract::In this study, we estimated the association between the inferred haplotypes in the inflammation, DNA repair, and folate pathways, and developed risk models for Hodgkin lymphoma. The study population consisted of 200 Hodgkin lymphoma cases and 220 controls. A susceptible association was observed on the XPC gene with ha...
journal_title:Leukemia research
pub_type: 杂志文章
doi:10.1016/j.leukres.2012.07.014
更新日期:2012-11-01 00:00:00
abstract::Ml cells were labeled in vitro with [3H]thymidine and injected into the peritoneal cavity of syngeneic mice. After several days the peritoneal cells were harvested and [3H]labeled cells were determined by autoradiography. The inoculated isotope-labeled Ml cells differentiated in the peritoneal cavity and lipopolysacch...
journal_title:Leukemia research
pub_type: 杂志文章
doi:10.1016/0145-2126(82)90050-9
更新日期:1982-01-01 00:00:00
abstract::Treatment of CMML remains a clinical challenge, with no drug demonstrating clear clinical benefit. Even if azacitidine is approved in the treatment of CMML, its role remains disputed. We report a cohort of 76 CMML patients (according to WHO classification) treated with azacitidine in 3 programs (French AZA compassiona...
journal_title:Leukemia research
pub_type: 临床试验,杂志文章
doi:10.1016/j.leukres.2013.01.004
更新日期:2013-06-01 00:00:00
abstract::We report a unique case of de novo acute promyelocytic leukemia (APL) with cryptic 15;17 rearrangements. Cytogenetically, structural rearrangements of the 6p23 region has been reported mainly in secondary leukemia. This patient had a karyotype of 46, XY, del(6)(p23) and no additional chromosomal abnormalities. Molecul...
journal_title:Leukemia research
pub_type: 杂志文章
doi:10.1016/s0145-2126(99)00139-3
更新日期:2000-01-01 00:00:00
abstract::Preclinical data suggest that all-trans retinoic acid (ATRA) synergizing with granulocyte colony stimulating factor (G-CSF), can improve the effectiveness of chemotherapy in acute myeloid leukemia (AML). Fludarabine 15 mg/m(2) is the minimum dose able to optimize intensification with fludarabine-arabinosylcytosine reg...
journal_title:Leukemia research
pub_type: 临床试验,杂志文章
doi:10.1016/j.leukres.2008.12.014
更新日期:2009-08-01 00:00:00
abstract::Ten patients with acute nonlymphocytic leukemia (ANLL) received bromodeoxyuridine (BrdU) at 100 mg/M2 intravenously over 1 h. BrdU is incorporated into the DNA by S-phase cells and was detected by using a monoclonal anti-BrdU antibody in the bone marrow aspirate (BM) and biopsy specimens obtained at the end of the inf...
journal_title:Leukemia research
pub_type: 杂志文章
doi:10.1016/0145-2126(87)90160-3
更新日期:1987-01-01 00:00:00
abstract::This study uses single cell network profiling (SCNP) to characterize biological pathways associated with in vitro resistance or sensitivity to chemotherapeutics commonly used in acute myeloid leukemia (AML) (i.e. cytarabine/daunorubicin, gemtuzumab ozogamicin (GO), decitabine, azacitidine, clofarabine). Simultaneous m...
journal_title:Leukemia research
pub_type: 杂志文章
doi:10.1016/j.leukres.2012.02.022
更新日期:2012-07-01 00:00:00
abstract::A diagnosis of myelodysplastic syndrome was made in an 18-year-old patient with Warkany syndrome due to constitutional trisomy 8 mosaicism. The possible causal role of this particular chromosome constitution with respect to myelodysplasia and embryonal childhood tumors is discussed. ...
journal_title:Leukemia research
pub_type: 杂志文章
doi:10.1016/0145-2126(95)00050-x
更新日期:1995-10-01 00:00:00
abstract::A primary mitochondrial defect may be pivotal in the pathogenesis of acquired idiopathic sideroblastic anemia (AISA). The mitochondrial respiratory chain is involved in mitochondrial iron uptake and supply of ferrous iron (Fe2+) for heme synthesis. Mitochondrial DNA (mtDNA) comes into play because several subunits of ...
journal_title:Leukemia research
pub_type: 杂志文章,评审
doi:10.1016/s0145-2126(99)00160-5
更新日期:2000-02-01 00:00:00
abstract::Media conditioned by regenerating murine bone marrow cells contain a stimulator of haemopoietic stem cell proliferation. Fractionated cell populations have been examined for production of this stimulatory activity in order to characterize its cellular source. The stimulator is produced by adherent, phagocytic, radiore...
journal_title:Leukemia research
pub_type: 杂志文章
doi:10.1016/0145-2126(82)90010-8
更新日期:1982-01-01 00:00:00
abstract::With the application of adequately sensitive tests, it is now becoming evident that more than 90% of patients with conventionally-defined polycythemia vera (PV) carry the somatic JAK2V617F mutation in their granulocytes. However, the specific mutation is also found in other classic and atypical myeloproliferative diso...
journal_title:Leukemia research
pub_type: 杂志文章
doi:10.1016/j.leukres.2006.01.004
更新日期:2006-06-01 00:00:00
abstract::Mutations in Janus kinase 2 (JAK2) are implicated in the pathogenesis of Philadelphia-chromosome negative myeloproliferative neoplasms, including primary myelofibrosis, polycythemia vera, and essential thrombocythemia. Gandotinib (LY2784544), a potent inhibitor of JAK2 activity, shows increased potency for the JAK2V61...
journal_title:Leukemia research
pub_type: 杂志文章,多中心研究
doi:10.1016/j.leukres.2017.08.010
更新日期:2017-10-01 00:00:00
abstract::While MDS was only recently viewed as an orphan disease without any FDA approved therapeutic options, the landscape has changed dramatically with a promise for development of exciting new therapeutics that parallels our growing understanding of the pathobiology of the disease. An array of new agents is entering clinic...
journal_title:Leukemia research
pub_type: 杂志文章,评审
doi:10.1016/j.leukres.2012.08.010
更新日期:2012-12-01 00:00:00
abstract::Twenty-three patients with acute myelogenous leukemia (AML) in first relapse were treated with high-dose cytosine-arabinoside (Ara-C) and amsacrine or idarubicin. To prime the cells, the patients were given rhGM-CSF. We studied the influence of 48-h infusion of rhGM-CSF on proliferation and Ara-C sensitivity of leukem...
journal_title:Leukemia research
pub_type: 临床试验,杂志文章
doi:10.1016/0145-2126(96)00005-7
更新日期:1996-06-01 00:00:00
abstract::Mantle cell lymphoma (MCL) an incurable B-cell, non-Hodgkin lymphoma (NHL) urgently requires new treatments. We assessed reovirus mediated oncolysis in a panel of human MCL cell lines. In vitro, we found the cytopathic effect of reovirus infection ranged from high to very limited and correlated with levels of Ras acti...
journal_title:Leukemia research
pub_type: 杂志文章
doi:10.1016/j.leukres.2009.05.020
更新日期:2010-01-01 00:00:00
abstract::Our retrospective analysis explored the role of leukemia cutis (LC) in disease progression of chronic myelomonocytic leukemia (CMML). Of 108 patients with CMML, 11 patients (10.2%) had LC including its equivalent (2 patients). Four of these patients developed acute myeloid leukemia (AML) within 0-4 months. The remaini...
journal_title:Leukemia research
pub_type: 杂志文章,评审
doi:10.1016/j.leukres.2011.05.003
更新日期:2012-01-01 00:00:00
abstract::We have recently described that a variant of L1210 leukemia cell (L1210/LN-1) originally fused with Lesch-Nyhan fibroblast is highly immunogenic for inducing tumor-specific transplantation immunity in (BALB/cxDBA/2)F1 mice. This finding has clearly been confirmed in the present study by in-vitro cell-mediated cytotoxi...
journal_title:Leukemia research
pub_type: 杂志文章
doi:10.1016/0145-2126(85)90316-9
更新日期:1985-01-01 00:00:00
abstract::We recently confirmed that ciclopirox olamine inhibits Wnt/beta catenin signalling in myeloma. Griseofulvin (GF) has similar chemical features as compared to ciclopirox olamine. In this study the anti-tumor effect of GF was investigated. GF demonstrated a major apoptotic activity in various human and murine myeloma an...
journal_title:Leukemia research
pub_type: 杂志文章
doi:10.1016/j.leukres.2010.10.008
更新日期:2011-08-01 00:00:00
abstract::To examine the relationship between viability of acute myelogenous leukemia (AML) blasts in liquid suspension culture and the occurrence of myeloid maturation in culture, total and differential cell counts and viability as determined by trypan blue dye exclusion were followed over 21 days of culture. A significant pos...
journal_title:Leukemia research
pub_type: 杂志文章
doi:10.1016/0145-2126(88)90098-7
更新日期:1988-01-01 00:00:00
abstract::Beagle dogs were treated with recombinant human interleukin 2 (IL-2) 6 x 10(6) International Units (IU)/day for 7 consecutive days following conditioning with sublethal (200 cGy) or lethal (400 cGy) doses of high-dose rate whole body irradiation (WBI) and reconstitution with 2 x 10(8)/kg autologous bone marrow cells, ...
journal_title:Leukemia research
pub_type: 杂志文章
doi:10.1016/0145-2126(92)90075-i
更新日期:1992-10-01 00:00:00
abstract::Chlorambucil-induced apoptosis was assessed by three different flow cytometric methods in B-cell chronic lymphocytic leukaemia (B-CLL) cells cultured in vitro and the results were compared with those derived from the morphological assessment of the same samples. Spontaneous apoptosis was consistently observed in the c...
journal_title:Leukemia research
pub_type: 杂志文章
doi:10.1016/s0145-2126(98)00013-7
更新日期:1998-05-01 00:00:00
abstract::This is the case report of a 47-year-old woman referred to our institution due to acute liver failure related to imatinib, who was submitted to a successful liver transplantation. Nilotinib was safely used post-transplant. ...
journal_title:Leukemia research
pub_type: 信件
doi:10.1016/j.leukres.2009.06.012
更新日期:2009-12-01 00:00:00
abstract::We performed a comprehensive cost calculation identifying the main cost drivers of treatment of chronic lymphocytic leukaemia in daily practice. In our observational study 160 patient charts were reviewed repeatedly to assess the treatment strategies from diagnosis till the study end. Ninety-seven patients (61%) recei...
journal_title:Leukemia research
pub_type: 杂志文章
doi:10.1016/j.leukres.2013.10.029
更新日期:2014-01-01 00:00:00
abstract::Acute promyelocytic leukemia (APL) is highly malignant and frequently expresses the PML-RARalpha (promyelocytic leukemia-retinoic acid receptor-alpha) fusion protein. This fusion protein is targeted by all-trans retinoic acid (ATRA) and arsenic trioxide (As2O3), presently used in APL therapy. We have evaluated effects...
journal_title:Leukemia research
pub_type: 杂志文章
doi:10.1016/j.leukres.2007.06.021
更新日期:2008-02-01 00:00:00
abstract::High CD23 expression is a hallmark of B-CLL cells. It is lost during in vitro culture and can be reinduced by IL-4, albeit to a lower extent than in normal B cells. To elucidate the events controlling CD23 expression in B-CLL cells, the IL-4 mediated induction of STAT6 was investigated. Western-blot analysis demonstra...
journal_title:Leukemia research
pub_type: 杂志文章
doi:10.1016/s0145-2126(99)00191-5
更新日期:2000-04-01 00:00:00
abstract::Peripheral neuropathy (PN), with neuropathic pain as main symptom, represents the dose-limiting toxicity of the proteasome inhibitor bortezomib. Aim of this study was to compare the incidence, risk factors, severity and outcome of PN and neuropathic pain in patient treated with bortezomib up-front or at relapse. We st...
journal_title:Leukemia research
pub_type: 杂志文章
doi:10.1016/j.leukres.2009.07.022
更新日期:2010-04-01 00:00:00
abstract::Several genetic polymorphisms in the genes coding folate-metabolizing enzymes have been associated with susceptibility to hematology malignancies. We conducted a Korean population-based case-control study to examine the relationship between the polymorphisms of folate-metabolizing enzymes and the risk of AML (acute my...
journal_title:Leukemia research
pub_type: 杂志文章
doi:10.1016/j.leukres.2008.07.026
更新日期:2009-01-01 00:00:00
abstract::In this study we explored the effects of bryostatin-5 on the clonogenic response of normal bone marrow mononuclear (BM) cells and HL60 myeloid leukemia cells. Leukemic HL60 colony formation was strongly inhibited by bryostatin-5 depending on dose and schedule. An inhibitory effect on HL60 colony formation was readily ...
journal_title:Leukemia research
pub_type: 杂志文章
doi:10.1016/0145-2126(94)00118-t
更新日期:1995-01-01 00:00:00
abstract::To further understand the role of XIAP in acute myeloid leukemia (AML), we suppressed XIAP expression by antisense oligonucleotides and determined the effect on gene expression profiles and biological pathways. XIAP inhibition upregulated expression of proteasome genes in a manner similar to the proteasome inhibitor b...
journal_title:Leukemia research
pub_type: 杂志文章
doi:10.1016/j.leukres.2013.04.018
更新日期:2013-08-01 00:00:00